CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

BRCA1/2 mutation (first-line mCRPC — PARP + AR combination)

Gene: BRCA1/BRCA2 · Type: mutation

Indications: Prostate cancer

SensitivityResistanceCIViC Context

FDA Sensitivity Assertions

DrugIndicationRecommendationFDA SourceLink
OlaparibProstate cancerINDICATED
FDA Label
Label
AbirateroneProstate cancerINDICATED
FDA Label
Label
NiraparibProstate cancerINDICATED
FDA Label
Label